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Abstract Improvements in screening and adjuvant ther-
apy for breast cancer are associated with decreased recur-
rence, which may have the effect of increasing the
proportion of patients presenting with first-line de novo
versus recurrent metastatic breast cancer (MBC). Here, we
describe and compare patients with de novo versus recur-
rent human epidermal growth factor 2 (HER2)-positive
MBC. registHER was a prospective observational cohort
study (late 2003–early 2006) of 1,023 patients with HER2-
positive MBC. Baseline characteristics, treatment patterns,
and clinical outcomes were examined in patients with
newly diagnosed de novo (n = 327) compared with
recurrent HER2-positive MBC after prior treatment for
early-stage disease (n = 674). Patients with de novo
HER2-positive MBC were less likely to have lung
metastases, more likely to have lymph node, bone, and/or
liver metastases and[4 sites of metastases and more likely
to receive combined or concurrent chemotherapy and
hormonal therapy with or without trastuzumab than those
with recurrent HER2-positive MBC. Median follow-up was
29 months. Median progression-free survival was 12.1
versus 9.3 months [hazard ratio = 0.716 (95 % confidence
interval (CI) 0.617–0.831)], and overall survival was 41.7
versus 32.8 months [hazard ratio = 0.766 (95 % CI
0.633–0.928)] for patients with de novo versus recurrent
HER2-positive MBC, respectively. Patients with recurrent
HER2-positive MBC had similar outcomes regardless of
whether they received prior adjuvant therapy, excluding
hormonal therapy. Despite presenting with more advanced-
stage disease and higher tumor burdens, patients with de
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novo HER2-positive MBC have more favorable clinical
outcomes than those with recurrent HER2-positive MBC.
These differences may be due to effects of prior drug
exposure and could have implications for designing and
interpreting clinical trials.
Keywords Metastatic breast cancer  Observational
study  De novo MBC  Recurrent MBC  registHER 
HER2-positive
Introduction
Data from the last 20 years have shown a decrease in
mortality from breast cancer in the United States of more
than 30 % from its peak, at least in part because of better
screening and treatments [1, 2]. Breast cancer remains the
most common type of cancer diagnosed in women and is
expected to account for *29 % of new US cancer cases in
2013 [1]. Earlier identification of the disease and
improvements in local and adjuvant therapy [2–7] have
resulted in decreasing rates of relapse in patients with
early-stage breast cancer. This effectively increases the
proportion of patients who initially present with de novo
first-line metastatic breast cancer (MBC) in the overall
MBC patient population. This overall shift could have
implications on treatment choices and the design and
interpretation of results from clinical trials in the MBC
setting.
Human epidermal growth factor receptor 2 (HER2),
overexpressed in approximately 15–20 % of breast cancer
cases, is a predictive and prognostic marker of treatment
outcomes [8–13]. Prior to the introduction of HER2-tar-
geted therapy, the prognosis for patients with HER2-posi-
tive MBC was markedly worse compared with that for
patients with HER2-negative MBC [10, 11]. Since the
approval of trastuzumab for MBC by the US Food and
Drug Administration in 1998, the repertoire of HER2-tar-
geted treatments for HER2-positive MBC has expanded to
include lapatinib [14], pertuzumab [15], and trastuzumab
emtansine [16], in 2007, 2012, and 2013, respectively. In
addition, trastuzumab use in the adjuvant setting [3–5] was
approved in 2006, and pertuzumab was approved in the
neoadjuvant setting in 2013. As treatments for HER2-
positive breast cancer continue to improve, it is important
to understand the evolution of the natural history of
patients with de novo or recurrent HER2-positive MBC in
a real-world setting.
The registHER observational cohort study, which
enrolled patients with newly diagnosed HER2-positive
MBC between late 2003 and early 2006, offers a unique
opportunity to describe and compare patient demographics,
clinical characteristics, prior and first-line MBC treatment
patterns, and clinical outcomes in patients presenting with
de novo or recurrent HER2-positive MBC prior to the
approval of adjuvant trastuzumab for the treatment of
early-stage breast cancer. By investigating the natural
history of de novo and recurrent HER2-positive MBC, this
analysis may help us to understand and interpret results
from current and future clinical studies in this patient
population.
Methods
Study design and patients
registHER was a multicenter, prospective, US-based
observational cohort study of 1,023 patients with HER2-
positive MBC who were recruited from community and
academic settings between December 2003 and February
2006. Study design and recruitment details are described in
depth elsewhere [17]. The objectives were to examine the
natural history, treatment patterns, and outcomes of
patients with HER2-positive MBC in the clinical practice
setting. Patients were enrolled within 6 months of diag-
nosis of HER2-positive MBC and observed until death,
disenrollment, or the study end date of June 2009. Patients
received treatment based on the standard practice of their
physician and without scheduled study-specified evalua-
tions. Prior or planned treatment with any specific HER2-
directed therapy was not a requirement for enrollment. All
enrolled patients provided informed consent.
Patient information was collected at enrollment and
every 3 months thereafter. The evaluation schedule and
tumor response were reported by the treating physicians
according to their standard practice and judgment.
Statistical analysis
This analysis incorporates data from the June 15, 2009,
database lock. Only patients reported to have received
MBC treatment during the study were included in this
analysis. Patients with de novo HER2-positive MBC were
defined as those with B90 days between the initial diag-
nosis of early-stage breast cancer and the diagnosis of
MBC (i.e., they likely had occult metastatic disease at the
time of initial diagnosis). Patients with recurrent HER2-
positive MBC were defined as those with [90 days
between the early-stage breast cancer and MBC diagnoses.
A 90-day cutoff was used to differentiate de novo and
recurrent HER2-positive MBC, because early breast cancer
staging information was missing from the records of 215
patients.
Descriptive analyses of demographic and clinical char-
acteristics at MBC diagnosis, tumor staging, biomarkers
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and treatment history (including prior early-stage breast
cancer treatment for patients with recurrent HER2-positive
MBC), first-line MBC treatment patterns, and tumor
response were performed. Hormone receptor (HR) status
was determined according to individual institutional crite-
ria. The term ‘‘HR-positive’’ was defined as estrogen
receptor [ER]-positive and/or progesterone receptor [PR]-
positive; ‘‘HR-negative’’ was defined as ER-negative and
PR-negative. First-line MBC treatment patterns were based
on treatment received before first disease progression but
after MBC diagnosis; treatment may have been given
sequentially or concurrently. Median progression-free sur-
vival (PFS), overall survival (OS), and their corresponding
95 % confidence intervals (CIs) were estimated by the
Kaplan–Meier method. ‘‘PFS’’ was defined as the time
from MBC diagnosis to first progression reported by phy-
sicians’ standard practice or death from any cause,
whichever occurred first. PFS data for patients without
disease progression or death as of the database lock date
were censored at the time of the last tumor response
evaluation. ‘‘OS’’ was defined as the time from MBC
diagnosis to the date of death from any cause. OS data for
patients without an event as of the database lock date were
censored at the time of the last follow-up. Estimates of best
first-line response rates were calculated. Univariate and
multivariate Cox regression analyses were used to generate
unadjusted and adjusted hazard ratios and their corre-
sponding 95 % CIs. Two multivariate Cox regression
analyses for PFS and OS adjusted for age at enrollment,
race, Eastern Cooperative Oncology Group performance
status (ECOG PS), HR status, visceral/nonvisceral sites,
and number of metastatic sites at diagnosis. These covar-
iates were chosen for the multivariate Cox regression
analysis on the basis of the covariates’ clinical significance
rather than statistical significance.
After using disease-free interval to stratify patients with
de novo or recurrent HER2-positive MBC, it became
apparent that 24 patients with de novo HER2-positive
MBC had initially been staged as early breast cancer and
treated with adjuvant or neoadjuvant therapy immediately
prior to their metastatic diagnosis. To ensure that the
inclusion of these 24 patients did not impact the overall
outcomes reported for the other patients with de novo
HER2-positive MBC, a sensitivity analysis was performed.
Results
Baseline characteristics and treatment history
Of the 1,023 patients enrolled in registHER, 22 patients
were not reported to have received MBC treatment during
the study and were excluded from this analysis
(N = 1,001). Baseline demographics and clinical charac-
teristics for the registHER cohort were examined for the
327 (33 %) patients presenting with de novo and 673
(67 %) with recurrent HER2-positive MBC (Table 1). A
higher proportion of patients with de novo versus recurrent
HER2-positive MBC were \50 years old, non-white, had
an ECOG PS of 0 or 1, had HR-positive disease, and had
Table 1 Baseline patient demographics and clinical characteristics
Characteristic, n (%) De novo patients
(n = 327)
Recurrent patients
(n = 674)
Age at study enrollment
\50 years 133 (40.7) 246 (36.5)
50–64 years 132 (40.4) 276 (40.9)
C65 years 62 (19.0) 152 (22.6)
Race
White 251 (76.8) 542 (80.4)
Black 49 (15.0) 77 (11.4)
Other 27 (8.3) 55 (8.2)
ECOG PS
0–1 171 (52.3) 284 (42.1)
C2 24 (7.3) 36 (5.3)
Missing 132 (40.4) 354 (52.5)
Node status at initial diagnosis
Positive 137 (41.9) 378 (56.1)
Negative 14 (4.3) 196 (29.1)
Unknown 176 (53.8) 100 (14.8)
HR status at initial diagnosis
Positive 180 (55.0) 349 (51.8)
Negative 136 (41.6) 297 (44.1)
Unknown/missing 11 (3.4) 28 (4.2)
Number of metastatic disease sites
1 114 (34.9) 346 (51.3)
2 99 (30.3) 174 (25.8)
3 58 (17.7) 98 (14.5)
C4 56 (17.1) 56 (8.3)
Site of metastatic disease
Bone 181 (55.4) 269 (39.9)
Liver 154 (47.1) 246 (36.5)
Lung 88 (26.9) 229 (34.0)
Lymph nodes 111 (33.9) 167 (24.8)
Breast 93 (28.4) 38 (5.6)
Mediastinum 25 (7.6) 54 (8.0)
Central nervous system 17 (5.2) 55 (8.2)
Pleural effusion 19 (5.8) 36 (5.3)
Other abdominal 17 (5.2) 29 (4.3)
Pelvis 3 (0.9) 13 (1.9)
Ascites 2 (0.6) 3 (0.4)
Other 13 (4.0) 19 (2.8)
ECOG PS Eastern Cooperative Oncology Group performance status,
HR hormone receptor
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C4 metastatic disease sites. Patients with recurrent HER2-
positive MBC were more likely to be C65 years old, have a
single metastatic disease site, have node-positive disease,
and have HR-negative disease. Patients with de novo
HER2-positive MBC were more likely to have metastatic
disease in the lymph nodes, bone, or liver, while patients
with recurrent HER2-positive MBC were more likely to
have metastatic sites in the lung and central nervous system
(CNS).
Of the 587 patients with recurrent HER2-positive MBC
who received therapy in the adjuvant or neoadjuvant set-
tings (Table 2), only 55 (9.4 %) received chemotherapy
with trastuzumab: 40 (72.7 %) patients were treated with
doxorubicin and cyclophosphamide (AC) with trastuzumab
and of these, 37 (67.3 %) received AC plus a taxane (ACT)
with trastuzumab. Eleven (20.0 %) patients received
adjuvant hormonal therapy with chemotherapy. In total,
532 patients with recurrent HER2-positive MBC received
non-trastuzumab-based adjuvant or neoadjuvant regimens.
Of these 532 patients, 470 received chemotherapy: 396
(74.4 %) received AC, and of these, 248 (46.6 %) were
treated with ACT. In addition, of the 532 patients, 60
(11.3 %) received adjuvant hormonal therapy only and 164
(30.8 %) received hormonal therapy with chemotherapy.
First-line MBC treatment patterns
Treatment patterns for first-line metastatic disease were
compared between patients presenting with de novo and
those with recurrent HER2-positive MBC (Table 3).
Although the proportions of patients who received only
trastuzumab plus chemotherapy were similar between the
two groups (59 % each), more patients with de novo vs
recurrent HER2-positive MBC were treated with both
chemotherapy and hormonal therapy (either concurrently
or sequentially) with and without trastuzumab (22.9 vs
13.8 % and 2.4 vs 0.9 %, respectively). The proportion of
patients who received sequential versus concurrent hor-
monal therapy with trastuzumab-based regimens was sim-
ilar between the two groups. Fewer patients with de novo
versus recurrent HER2-positive MBC were treated with
trastuzumab alone in the first-line MBC setting (2.4 vs
9.2 %). The most commonly used trastuzumab-based
combination chemotherapy for both groups was a taxane
and a platinum agent doublet. The next most common
trastuzumab-based regimens were trastuzumab with vino-
relbine for patients with recurrent HER2-positive MBC and
trastuzumab with docetaxel for patients with de novo
HER2-positive MBC.
Table 2 Prior adjuvant or neoadjuvant therapies for patients with
recurrent HER2-positive MBC
Treatment, n (%) Recurrent
patients
(n = 587)
Trastuzumab-based regimens n = 55
With chemotherapy only 44 (80.0)
With hormonal therapy only 0
With chemotherapy and hormonal therapy 11 (20.0)
Trastuzumab alone 0
Non–trastuzumab-based regimens n = 532
Chemotherapy only 306 (57.5)
Hormonal therapy only 60 (11.3)
Chemotherapy and hormonal therapy 164 (30.8)
Trastuzumab with specific chemotherapy regimens n = 55
AC 40 (72.7)
ACT 37 (67.3)
Docetaxel 34 (61.8)
Paclitaxel 19 (34.5)
Specific chemotherapy regimens without trastuzumab n = 532
AC 396 (74.4)
ACT 248 (46.6)
Docetaxel 146 (27.4)
Paclitaxel 148 (27.8)
AC doxorubicin and cyclophosphamide, ACT AC and a taxane, HER2
human epidermal growth factor receptor 2
Table 3 First-line treatment for MBC
Treatment, n (%) De novo
patients
(n = 327)
Recurrent
patients
(n = 674)
Trastuzumab-based regimens n = 288 n = 592
With chemotherapy only 193 (59.0) 398 (59.1)
With hormonal therapy only 12 (3.7) 39 (5.8)
With chemotherapy and hormonal
therapy
75 (22.9) 93 (13.8)
Sequential hormonal therapy 50 (66.7) 60 (64.5)
Concurrent hormonal therapy 25 (33.3) 33 (35.5)
Trastuzumab alone 8 (2.4) 62 (9.2)
Non-trastuzumab-based regimens n = 39 n = 82
Chemotherapy only 18 (5.5) 35 (5.2)
Hormonal therapy only 13 (4.0) 41 (6.1)
Chemotherapy and hormonal therapy 8 (2.4) 6 (0.9)
Trastuzumab and specific chemotherapy
combinations
n = 268 n = 491
Taxane/platinum 70 (26.1) 107 (21.8)
Docetaxel 23 (8.6) 39 (7.9)
Anthracycline/cyclophosphamide/
taxane
21 (7.8) 3 (0.6)
Paclitaxel 18 (6.7) 38 (7.7)
Vinorelbine 13 (4.9) 75 (15.3)
First-line therapy is the regimen received between the date of the first
treatment following the diagnosis of metastasis and the date of first
disease progression
728 Breast Cancer Res Treat (2014) 145:725–734
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Clinical outcomes
Median follow-up was 29 months (range 0.5–60.9). Med-
ian PFS was longer for patients with de novo (12.1 months;
95 % CI 11.4–13.5) versus recurrent (9.3 months; 95 % CI
8.1–10.0) HER2-positive MBC (Fig. 1). The unadjusted
hazard ratio was 0.733 (95 % CI 0.635–0.847), favoring
patients with de novo HER2-positive MBC. Median OS
was 41.7 months (95 % CI 36.1–47.2) versus 32.8 months
(95 % CI 29.3–36.7) for patients with de novo versus
recurrent HER2-positive MBC, respectively (Fig. 2). The
unadjusted HR was 0.775 (95 % CI 0.643–0.935), also
favoring patients with de novo HER2-positive MBC. The
adjusted PFS hazard ratio was 0.716 (95 % CI
0.617–0.831) (Fig. 3). The adjusted OS hazard ratio was
0.766 (95 % CI 0.633–0.928) (Fig. 4). A higher percentage
of patients with de novo versus recurrent HER2-positive
MBC had a complete response or a partial response/stable
disease as their best first-line response (82.9 vs 72.7 %;
Table 4).
Median PFS [9.3 (95 % CI 8.0–10.0) vs 9.7 months
(95 % CI 6.7–11.1)] and OS [32.8 (95 % CI 28.7–36.8) vs
33.8 months (95 % CI 27.7–41.7)] were similar for patients
with recurrent HER2-positive MBC who received prior
adjuvant therapy (n = 541) versus those who did not
(n = 133). When analyzed according to HR status, patients
in both the de novo and recurrent groups with HR-positive
disease generally had longer median PFS and OS than
patients with HR-negative disease (Table 5). For patients
with HR-positive disease, those presenting with de novo
MBC had longer median PFS [14.4 (95 % CI 11.8–19.0) vs
9.9 months (95 % CI 8.8–11.4)] and OS [52.9 (95 % CI
43.8–not available [NA]) versus 37.7 months (95 % CI
33.7–41.7)] than patients with recurrent MBC. For patients
in the recurrent group with HR-positive disease who had
received adjuvant therapy, median OS was longer for those
who had received adjuvant hormonal therapy [40.3 months
(95 % CI 32.8–43.8)] versus those who had not
[34.6 months (95 % CI 25.6–41.5)]. Median OS was the
shortest for patients in the recurrent group with HR-nega-
tive disease who had received adjuvant therapy
[26.6 months (95 % CI 23.9–33.9)].
In patients with de novo HER2-positive MBC, the site
of first disease progression was most frequently bone/breast
and less frequently visceral sites compared with patients
with recurrent HER2-positive MBC (Table 6). Time to first
CNS progressive disease was 11.8 months (95 % CI
9.7–13.5) for patients with de novo HER2-positive MBC
versus 7.7 months (95 % CI 6.9–10.5) for patients with
recurrent HER2-positive MBC. When adjusted for baseline
demographics or clinical characteristics, the multivariate
Cox regression analysis demonstrated that the hazard of
progression and death in patients with de novo HER2-
positive MBC were lower than that for recurrent HER2-
positive MBC by 28 and 23 %, respectively (Figs. 2, 4). In
addition, the following characteristics were also associated
with more favorable clinical outcomes: younger age, white
race, an ECOG PS of 0 or 1, HR-positive disease, non-
visceral disease, and fewer metastatic disease sites.
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Table 4 Best response to first-line treatment for MBC
Best response, n (%) De novo patients
(n = 327)
Recurrent patients
(n = 674)
Complete response 70 (21.4) 105 (15.6)
Partial response/stable
disease
201 (61.5) 385 (57.1)
Progressive disease 48 (14.7) 162 (24.0)
No assessment 8 (2.4) 22 (3.3)
Best observed response confirmed by clinical symptoms, physical
examination, or radiology
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Sensitivity analysis
There were no noticeable differences between the baseline and
clinical characteristics of patients with de novo HER2-positive
MBC in the overall analysis compared with those in the sensi-
tivity analysis that excluded the 24 patients with de novo MBC
later found to be treated with adjuvant or neoadjuvant therapy
(data not shown). The sensitivity analysis showed that these
patients had slightly longer median PFS and OS compared with
patients in the overall analysis: median PFS was 12.5 months
(95 % CI 11.4–13.8), and median OS was 42.0 months (95 % CI
36.9–NA). For best first-line response, 63 (20.8 %) had complete
response, 186 (61.4 %) had partial response/stable disease, 46
(15.2 %) had progressive disease, and 8 (2.6 %) had no assess-
ment. While the proportion of patients with CNS metastases at
first disease progression in the sensitivity analysis remained
similar to that in the overall analysis (17.5 %), the median time to
CNS metastases was higher at 13.0 months (95 % CI 9.3–14.5).
Discussion
The registHER observational cohort study provides a
unique opportunity to examine the natural disease history,
first-line MBC treatment patterns, and clinical outcomes
for patients presenting with de novo or recurrent HER2-
positive MBC in a real-world population. Despite pre-
senting with more advanced-stage disease with a higher
tumor burden at first diagnosis, patients with de novo
HER2-positive MBC had a 28 and 23 % lower hazard of
progression and death, respectively, compared with
patients with recurrent HER2-positive MBC.
One possible explanation for poorer outcomes for
patients with recurrent HER2-positive MBC may be that
their metastatic disease is more resistant and/or refractory
owing to the selection of more resistant or aggressive
Table 5 PFS and OS in patients with recurrent HER2-positive MBC by HR status and prior adjuvant therapy
Recurrent group (n=674) De novo group (n=327)
Median PFS, months (95% 
CI) 9.3 (8.1–10.0) 12.1 (11.4–13.5)
Median OS, months (95% CI) 32.8 (29.3–36.7) 41.7 (36.1–47.2)
HR-positivea
(n=349)
HR-negativea
(n=297) HR-positive (n=180) HR-negative (n=136)
Median PFS, months (95% 
CI) 9.9 (8.8–11.4) 7.8 (7.0–9.3) 14.4 (11.8–19.0) 11.3 (9.3–12.3)
Median OS, months (95% CI) 37.7 (33.7–41.7) 27.1 (24.4–32.5) 52.9 (43.8–NA) 30.8 (27.2–37.5)
Adjuvant therapy
(n=295)
No adjuvant
therapy (n=54)
Adjuvant
therapy (n=224)
No adjuvant
therapyb (n=73)
Median PFS, months (95% 
CI) 9.9 (8.8–11.6) 10.0 (6.4–12.6) 7.7 (6.9–9.2) 9.2 (6.0–11.1)
Median OS, months (95% CI) 37.5 (32.8–41.5) 38.9 (27.9–NE) 26.6 (23.9–33.9) 30.7 (20.1–41.7)
Adjuvant hormonal 
therapy
(n=201)
No adjuvant 
hormonal
therapy (n=94)
Median PFS, months (95% 
CI) 9.9 (8.2–11.7) 10.0 (7.3–12.7)
Median OS, months (95% CI) 40.3 (32.8–43.8) 34.6 (25.6–41.5)
CI confidence interval; HR hormone receptor; NE not estimable; OS overall survival; PFS progression-free survival
a There were 28 patients with missing or unknown HR status
b Includes patients who did not receive or report the receipt of adjuvant therapy
Table 6 Sites of first disease progression following first-line therapy
for HER2-positive MBC
Site at progressive
disease, n (%)
De novo patients
(n = 327)
Recurrent patients
(n = 674)
Bone/breast only 103 (31.5) 174 (25.8)
Visceral 73 (22.3) 226 (33.5)
Any central nervous system 57 (17.4) 105 (15.6)
Node/local 16 (4.9) 61 (9.1)
Other sites 0 (0) 1 (0.1)
Site of first disease progression after metastatic diagnosis HER2
human epidermal growth factor receptor 2
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clones of recurrent cells as a consequence of prior adju-
vant chemotherapy treatment. Effectively addressing
treatment resistance resulting from the selective effect of
therapy on clonal evolution in a heterogeneous tumor is
one of the great challenges of oncology medicine [18].
Intrinsic insensitivity may also be an obstacle to the
effective treatment of HER2-positive disease [19, 20].
Additional predictive markers for response to HER2-
Number of metastatic sites: 1
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Race: White
Age: <50 years 
Recurrent group
Reference
Number of metastatic sites: ≥4
Number of metastatic sites: 3
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Fig. 3 Multivariate Cox
regression analyses for
progression-free survival with
adjusted hazard ratios. CI
confidence interval, ECOG PS
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Fig. 4 Multivariate Cox
regression analyses for overall
survival with adjusted hazard
ratios. CI confidence interval,
ECOG PS Eastern Cooperative
Oncology Group performance
status, HR hormone receptor
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directed therapies are being studied, and these may help
to identify patients with refractory disease in the future
[21].
In registHER, patients presenting with de novo HER2-
positive MBC had longer PFS and OS in the first-line
setting than patients with recurrent MBC regardless of
whether they had received prior adjuvant treatment (PFS:
12.1 vs 9.3 months and OS: 41.7 vs 32.8 months, respec-
tively; see Table 5). This trend is nuanced, however, when
OS is examined by HR status. For HR-negative disease, the
median OS for patients with de novo MBC was similar to
that of patients with recurrent MBC who did not receive
adjuvant therapy (30.8 vs 30.7 months); both were longer
than patients who did receive adjuvant therapy
(26.6 months), suggesting selection of more aggressive
disease with therapy. Interestingly, when comparing
patients with HR-positive disease in the de novo group
with those in the recurrent group who had not received
adjuvant therapy, median OS was much longer for patients
in the de novo group (52.9 vs 38.9 months). Median OS
was also longer for patients in the recurrent group with HR-
positive disease who had received adjuvant hormonal
therapy (n = 201, 68.1 %) (who may have been expected
to have developed resistance) versus those who had not
(n = 94, 31.9 %) (40.3 vs 34.6 months). These results
raise the question of whether the difference in outcomes
between patients with de novo or recurrent HER2-positive
MBC is a result of treatment patterns or tumor character-
istics. In accordance with this, the results of a recent ret-
rospective analysis (N = 331) of women with de novo
stage IV or recurrent HER2-positive MBC also underscore
the impact of treatment patterns on clinical outcomes, even
if possible selection bias due to disease burden is taken into
account [22]. Although no differences in PFS or OS were
observed between patients with de novo or recurrent MBC
in that analysis, median OS was significantly longer for
patients with de novo MBC who received surgery
[60 months (95 % CI 41–79); n = 46] compared with
those who did not receive surgery [26 months (95 % CI
20–32); n = 31] and those with recurrent MBC [40 months
(95 % CI 37–43); n = 254] [22].
Due to the timing of the registHER study, only 55 of the
674 patients with recurrent HER2-positive MBC received
adjuvant or neoadjuvant trastuzumab. The addition of adju-
vant trastuzumab to chemotherapy decreases the risk of
recurrence in patients with HER2-positive early-stage breast
cancer compared with chemotherapy alone [3–5, 23] and, as
a result, is now well established as the standard of care in the
adjuvant setting, though*15 % of patients will still develop
metastases [20]. As fewer patients with early-stage breast
cancer relapse, it is likely that the ratio of patients presenting
with de novo HER2-positive MBC to those with recurrent
HER-positive MBC will increase. However, while relevant
clinical trials will have enrolled patients with both de novo
and recurrent HER2-positive MBC, few published data are
available providing this information. In an analysis of
patients with breast cancer diagnosed between 1992 and
2007, Dawood et al. [24] found that, of the patients with non-
missing HER2 status data (n = 563), 23 % of patients had de
novo stage IV HER2-positive disease and 77 % had relapsed
HER2-positive disease, based on staging information. In the
registHER population, enrolled between 2003 and 2006, the
proportion of patients with de novo versus recurrent HER2-
positive MBC was 33 vs 67 %, respectively. In the ran-
domized phase 2, TDM4450g study in patients treated with
trastuzumab emtansine or trastuzumab plus docetaxel who
were enrolled between 2008 and 2009, *30 % of patients
with non-missing staging data had de novo stage IV HER2-
positive MBC at initial diagnosis [25]. In that study, how-
ever, the number of patients with de novo HER2-positive
MBC may have been skewed because patients with an
interval \6 months from neoadjuvant or adjuvant chemo-
therapy or B21 days from prior trastuzumab therapy were
excluded from enrollment. Also, as an international study,
adjuvant therapy practice patterns may be different from the
US-based cohort.
To further characterize the changing face of HER2-posi-
tive MBC, especially in light of the standard use of trast-
uzumab for early-stage disease and the subsequent approvals
of additional HER2-targeted therapies (such as trastuzumab
emtansine in the metastatic setting and pertuzumab in the
metastatic and neoadjuvant settings), the Systematic Ther-
apies for HER2-Positive Metastatic Breast Cancer Study
(SystHERs; clinicaltrials.gov, NCT01615068) was planned.
SystHERs is a US-based multicenter, prospective observa-
tional cohort that began enrolling patients with HER2-
positive MBC in 2012. The data generated will reflect not
only standard trastuzumab use in the adjuvant setting but also
the evolving standard of dual HER2-targeted therapy in the
metastatic and neoadjuvant settings. Clinical outcomes and
characteristics inherent to patients with de novo HER2-
positive MBC remain of interest and may have to be taken
into account during the study design or data analysis of future
HER2-positive clinical trials.
The limitations of this analysis include the use of an
arbitrary 90-day cutoff to define patients with de novo or
recurrent HER2-positive MBC in order to account for
patients with occult de novo HER2-positive MBC. The
early-stage breast cancer and MBC dates used to calculate
the cutoff interval were collected retrospectively at study
enrollment. If the groups had been defined based on staging
information instead, the proportions of patients with de
novo vs recurrent HER2-positive MBC may have been
different. However, data such as those presented here could
ultimately provide a more evidence-based method to set
these types of criteria. In addition, this analysis was not
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preplanned in the protocol and thus lacks a predefined
hypothesis. As mentioned, the cutoff used led to the
inclusion of a small number of patients with occult de novo
HER2-positive MBC who were treated with adjuvant
therapy before their MBC diagnosis; however, as demon-
strated by the sensitivity analysis, the inclusion of these
patients did not affect the overall outcomes.
As the relative proportion of patients with de novo HER2-
positive MBC compared with recurrent HER2-positive MBC
is likely to increase, differences between the groups may
become more pronounced. These findings from registHER,
together with ongoing and upcoming studies—such as Sys-
tHERs—and advances in predictive markers for metastatic
treatments, may help in understanding the contributions of
tumor characteristics or treatment patterns to differences in de
novo and recurrent HER2-positive MBC. The outcomes of
these studies will help guide the effective management of
patients with HER2-positive MBC in the future.
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